8/14/2023 0 Comments New laba lama combine inhaler![]() KeywordsĪsthma, COPD, triple therapy, single-inhaler Article: However, there is a real risk that the use of single-inhaler triple therapy will expand the “one-size-fits-all” approach that has conditioned the prescriptive behavior of many doctors in the recent past, with little consideration of individual patient variability when making management decisions. Pivotal trials have shown that there is a role for triple therapy, mainly for single-inhaler triple therapy, in both COPD and asthma management. Three single-inhaler triple therapies-beclomethasone dipropionate/formoterol/glycopyrronium, fluticasone furoate/vilanterol/umeclidinium, and budesonide/glycopyrronium/formoterol - are available to treat COPD, whereas no single-inhaler triple therapy has yet been approved for use in asthma, but several trials have evaluated, or are exploring, this possibility. As there is well-documented evidence that triple therapy is effective in improving lung function and reducing the risk of exacerbation in patients with asthma and those with COPD, single-inhaler triple therapies have been developed mainly to increase adherence to treatment that often is low because of complexity introduced by the additional inhaler(s). ![]() “In summary, comparative data on trials of the new LAMA/ LABA FDC inhalers against one of the ICS/LABA combination inhalers (fluticasone plus salmeterol) are now available, and the results significantly favor the LAMA/ LABA inhalers in terms of efficacy (improvements in FEV1), patient-reported outcomes (TDI, mMRC), and quality of life measures (SGRQ),” concluded the study.A favorable pharmacological interaction between long-acting β 2 agonists, long-acting muscarinic receptor antagonists, and inhaled corticosteroids (ICSs) explains why triple therapy is effective both in chronic obstructive pulmonary disease (COPD) and asthma however, it has been documented that the presence of an ICS may cause the occurrence of pneumonia. Therefore, LAMA/LABA FDC is a more cost-effective option because of the reduction in long term adverse effects, including exacerbations, and the unpredictability of how much they can cost a COPD patient over time. LAMA/LABA inhalers decrease the risk of pneumonia by 33% to 67%, according to the analysis. “The new LAMA/LABA FDCs are now widely available and are a welcome addition to the options available for maintenance therapy in COPD.” “Given the significant adverse effects and increased incidence of pneumonia with long-term use of ICS, a favorable efficacy and safety profile of new LAMA/LABA FDCs versus ICS/LABA in COPD patients is very encouraging,” noted the researchers. Pnemonia rates, forced expiratory volume in 1 second (FEV 1), and other adverse events were also considered, and significant improvements were established in favor of the LAMA/LABA inhaler for COPD treatment. Annual exacerbation rates among participants treated with indacaterol/glycopyrronium, one type of LAMA/LABA inhaler, were lower than the fluticasone/salmeterol group in a study. The analysis found significant decreases in exacerbation rates in the long duration trials with the dual bronchodilator. ![]() Long-term use of ICS has demonstrated increased incidence of pneumonia and other adverse effects. ![]() ![]() The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.Ī new review published by Dove Press analyzes data from previous studies that draw comparisons between new therapies and ICS/LABA. As more long-term therapies for chronic obstructive pulmonary disease (COPD) are being developed, the results and efficacy of different therapies vary. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |